Click here: to donate by Credit Card
Or here: to donate by PayPal
Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794
Thank you very much and God bless you.
Posted on 07/02/2025 11:55:29 AM PDT by Red Badger
In a nutshell
Researchers successfully restored hearing in 10 deaf participants aged 18 months to 24 years using gene therapy, proving the treatment works beyond early childhood
All patients showed hearing improvements within one month, with some achieving nearly normal hearing and ability to have conversations without hearing aids
The therapy proved safe with only mild side effects, opening doors for treating other genetic forms of deafness in the future
========================================================================
NANJING, China — A groundbreaking clinical trial has achieved what many thought impossible: restoring meaningful hearing in people born profoundly deaf, including teenagers and young adults who were previously considered too old for such treatment.
Researchers in China successfully used gene therapy to improve hearing in 10 participants ranging from 18 months to nearly 24 years old, dramatically expanding the age range where this revolutionary treatment can work. Some patients went from being unable to hear anything to having conversations with their families within months of treatment.
“Participant 4 was able to carry on daily conversation with her mom 4 months after treatment without activating the cochlear implant and lipreading,” the researchers noted in their study published in Nature Medicine. Another patient could identify specific words like “scissors,” “excavator,” “tomato,” and “banana” just one month after receiving the therapy.
This represents a major breakthrough for people with a genetic condition called DFNB9 deafness. Unlike traditional hearing aids or cochlear implants that amplify or bypass damaged parts of the ear, this gene therapy actually repairs the underlying genetic defect causing deafness.
How This Gene Therapy Works for Deafness
DFNB9 deafness affects people born with faulty versions of the OTOF gene. This gene produces a protein called otoferlin that’s essential for transmitting sound signals from the ear to the brain. Without working otoferlin, the ear can’t properly convert sound waves into the electrical signals the brain needs to perceive hearing.
The treatment works by injecting a modified virus carrying healthy copies of the OTOF gene directly into the inner ear. The virus acts like a molecular delivery truck, carrying the healthy genes specifically to hair cells in the inner ear where they’re needed most.
Surgeons access the inner ear through the mastoid bone behind the ear, the same approach used for cochlear implant surgery. A hair-thin needle then delivers 30-40 microliters of the gene therapy solution through a thin membrane into the inner ear’s fluid-filled chambers.
Age Ranges: How Teens and Adults Responded
All 10 participants showed hearing improvements within the first month of treatment. On average, participants’ hearing improved from baseline levels of 106 decibels to 52 decibels. That’s roughly the difference between needing to shout to be heard and being able to have a normal conversation.
The therapy worked well beyond infancy and early childhood, ages previously thought to represent the only window for successful intervention. A 14.5-year-old participant improved from profound deafness to being able to hear sounds at 59 decibels, while a 23-year-old adult showed meaningful hearing gains.
However, participants between 5 and 8 years old showed the most dramatic improvements, with some achieving nearly normal hearing. Younger toddlers and older participants still benefited but showed more modest gains. As the researchers noted: “The poor outcome in these toddlers is counterintuitive, as younger ages should be associated with better outcomes because ‘young’ inner ears presumably have more complete cellular structure and better-preserved functions.”
Safety and Side Effects: What the Trial Found
Throughout the 12-month follow-up period, the treatment proved remarkably safe. All 162 adverse events reported were mild to moderate, with the most common being decreased neutrophil counts in blood tests. This is a manageable side effect that didn’t require treatment.
One participant received a second injection in the same ear four months after the first, demonstrating that repeat treatments are both safe and potentially beneficial for optimizing results. Most hearing improvement occurred within the first month, with benefits maintaining or slightly improving over the following months.
What This Means for Future Deafness Treatments While this gene therapy only works for DFNB9 deafness, which accounts for a small percentage of genetic hearing loss cases, the success opens doors for developing similar treatments for other genetic forms of deafness. The study represents a proof-of-concept that gene therapy can safely and effectively restore hearing when properly targeted.
“This is a huge step forward in the genetic treatment of deafness, one that can be life-changing for children and adults,” says Maoli Duan, a consultant and docent at the Karolinska Institutet, Sweden, and one of the study’s corresponding authors, in a statement. “Hearing was greatly improved in many of the participants, which can have a profound effect on their life quality. We will now be following these patients to see how lasting the effect is.”
For families affected by genetic hearing loss, this research transforms what was once a permanent condition into something that might be treatable, regardless of whether that person is 2 or 22 years old. The trial continues with plans to follow participants for five years to assess long-term safety and durability of hearing improvements.
With only 10 participants, including just one adult, larger trials are needed to confirm these results across diverse populations. Researchers are working to expand enrollment to better understand optimal timing and dosing strategies for this revolutionary approach to treating inherited deafness.
Paper Summary
Methodology
Researchers conducted a multicenter clinical trial across five hospitals in China, enrolling 10 participants aged 1.5 to 23.9 years with DFNB9 deafness caused by mutations in the OTOF gene. Participants received a single injection of AAV-OTOF gene therapy delivered directly into the inner ear through the round window membrane via a surgical approach through the mastoid bone. The treatment used a 1:1 mixture of two modified viruses carrying different parts of the healthy OTOF gene, with the complete gene reconstructed inside target cells.
Results
All participants showed hearing improvements within one month of treatment, with average hearing thresholds improving from 106 decibels to 52 decibels. The most dramatic improvements occurred in participants aged 5-8 years, with some achieving near-normal hearing. Even older participants, including a 14.5-year-old and 23-year-old, showed meaningful hearing gains. The therapy proved safe with 162 mild-to-moderate adverse events and no serious complications. Effects were rapid, with 62% of total hearing improvement occurring within the first month.
Limitations
The study had a small sample size of only 10 participants, including just one adult, limiting the ability to draw broad conclusions about effectiveness across different populations. Researchers couldn’t fully explain why younger toddlers and older participants showed more modest improvements compared to the 5-8 year age group. The treatment only applies to DFNB9 deafness, a relatively rare genetic condition, and long-term durability beyond 12 months remains to be established.
Funding and Disclosures
The study was funded by multiple Chinese research foundations and Otovia Therapeutics Inc., the company developing the gene therapy. Several authors are employees of Otovia Therapeutics, and the lead researcher serves as the company’s unpaid chief scientist. The commercial sponsor participated in study design and manuscript preparation.
Publication Information
The study was published in Nature Medicine on July 2, 2025. The clinical trial was registered at ClinicalTrials.gov under identifier NCT05901480 and remains ongoing with planned five-year follow-up. The research was conducted in accordance with international ethical guidelines and approved by ethics committees at all participating institutions.
Click here: to donate by Credit Card
Or here: to donate by PayPal
Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794
Thank you very much and God bless you.
CAN YOU HEAR ME NOW????...................
Ping!......................
Those crazy Chinese. I wonder which research facility in America they stole this from.
If this is true, it is very important.
I worked for a time with hearing impaired people, mostly elderly. Deafness can be more isolating than blindness.
Yes.
Unfortunately skepticism is merited because it’s China, even though it’s published in Nature Medicine.
We will see how this plays out. If it was indeed done in China then it will be done elsewhere in 1st world countries.
That’s wonderful news, this gene therapy.
I get the impression such gene therapy will not last for the remaining life of the patient. Perhaps just like Botox injections, the gene therapy for treating deafness is for short term duration only, and will require replenishment two or three times a year. That requirement may be frequent in the oncoming years.
It took at least five people in China to write this article.
If gene therapy can safely and effectively restore hearing, perhaps other genetic--and perhaps non-genetic--diseases can also be effectively treated and even cured.
Does it work on deaf cats?
From what I’ve read there is a lot of gene therapy research work in the USA and Europe to repair broken cilia in the inner ear. But it won’t be widely available to the public until sometime between 2030-2035.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.